Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at financialmarketpress.com, will continue to monitor these healthtech companies to see if the momentum continues. FinancialMarketPress.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent LEGN Stock Price: $57.25
Summary: Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Mitchell Kapoor analyst at H.C. Wainwright reiterates coverage on Legend Biotech (LEGN) stock in the energy sector with a Buy rating and has set LEGN's stock price target at $87.
TipRanks.com reports that Legend Biotech currently has 4 analysts offering 12-month price targets on LEGN and the consensus is a Strong Buy rating with an average stock price target of $90.25. The most recent LEGN stock price we have is $57.25 and we are not making any LEGN forecasts at this time.
In addition, TradingView issued a Buy rating for LEGN over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LEGN. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on LEGN, please click here >>
Medtronic, MDT
Recent MDT Stock Price: $78.62
Summary: Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
Ryan Zimmerman analyst at BTIG reiterates coverage on Medtronic (MDT) stock in the energy sector with a Hold rating and has not provided MDT's stock price target.
TipRanks.com reports that Medtronic currently has 3 analysts offering 12-month price targets on MDT and the consensus is a Moderate Buy rating with an average stock price target of $91.67. The most recent MDT stock price we have is $78.62 and we are not making any MDT forecasts at this time.
In addition, TradingView issued a Strong sell rating for MDT over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MDT. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MDT, please click here >>
Avita Medical, RCEL
Recent RCEL Stock Price: $10.17
Summary: AVITA Medical Inc. is a regenerative medicine company. It engages in developing and commercializing a technology platform which enables point-of-care autologous skin restoration for multiple unmet needs. AVITA Medical Inc., formerly known as AVITA Therapeutics Inc., is based in VALENCIA, Calif.
Matthew O'Brien analyst at Piper Sandler reiterates coverage on Avita Medical (RCEL) stock in the energy sector with a Buy rating and has set RCEL's stock price target at $19.
TipRanks.com reports that Avita Medical currently has 5 analysts offering 12-month price targets on RCEL and the consensus is a Strong Buy rating with an average stock price target of $24.80. The most recent RCEL stock price we have is $10.17 and we are not making any RCEL forecasts at this time.
In addition, TradingView issued a Strong Buy rating for RCEL over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RCEL. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on RCEL, please click here >>
Agilent, A
Recent A Stock Price: $123.92
Summary: Agilent Technologies, Inc. is an original equipment manufacturer of a broad-based portfolio of test and measurement products serving multiple end markets. Recently, the company has diversified into new end markets, namely industrial, chemical and electronics markets. The company has three business segments, including Life Sciences & Applied Markets Group (LSAG), Diagnostics and Genomics Group (DGG) and Agilent Cross Lab Group (ACG).The company uses a direct sales model for the distribution of its products, which is supplemented by distributors, resellers, manufacturers' representatives, telesales and electronic commerce, as necessary.
Catherine Ramsey analyst at Robert W. Baird reiterates coverage on Agilent (A) stock in the energy sector with a Buy rating and has set A's stock price target at $130.
TipRanks.com reports that Agilent currently has 5 analysts offering 12-month price targets on A and the consensus is a Moderate Buy rating with an average stock price target of $127.80. The most recent A stock price we have is $123.92 and we are not making any A forecasts at this time.
In addition, TradingView issued a Sell rating for A over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on A. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on A, please click here >>
Mainz Biomed B.V., MYNZ
Recent MYNZ Stock Price: $1.15
Summary: Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. Mainz Biomed N.V. is based in BERKELEY, Calif.
Ross Osborn analyst at Cantor Fitzgerald reiterates coverage on Mainz Biomed B.V. (MYNZ) stock in the energy sector with a Hold rating and has not provided MYNZ's stock price target.
TipRanks.com reports that Mainz Biomed B.V. currently has 2 analysts offering 12-month price targets on MYNZ and the consensus is a Moderate Buy rating with an average stock price target of $6.50. The most recent MYNZ stock price we have is $1.15 and we are not making any MYNZ forecasts at this time.
In addition, TradingView issued a Strong sell rating for MYNZ over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MYNZ. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on MYNZ, please click here >>
Bayer, BAYZF
Recent BAYZF Stock Price: $37.17
Summary: Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
Charles Bentley, analyst at Jefferies reiterates coverage on Bayer (BAYZF) stock in the energy sector with a Hold rating and has set BAYZF's stock price target at $40.52.
TipRanks.com reports that Bayer currently has 4 analysts offering 12-month price targets on BAYZF and the consensus is a Moderate Buy rating with an average stock price target of $58.59. The most recent BAYZF stock price we have is $37.17 and we are not making any BAYZF forecasts at this time.
In addition, TradingView issued a Strong sell rating for BAYZF over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BAYZF. financialmarketpress.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on BAYZF, please click here >>
The editors at financialmarketpress.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
FinancialMarketPress.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to FinancialMarketPress.com.
==============================================================================
